Literature DB >> 9614963

[No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].

E Heidemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9614963     DOI： 10.1007/bf03038727

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  6 in total

1.  Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.

Authors:  C K Osborne; L Kitten; C L Arteaga
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

2.  Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.

Authors:  K I Pritchard; A H Paterson; S Fine; N A Paul; B Zee; L E Shepherd; H Abu-Zahra; J Ragaz; M Knowling; M N Levine; S Verma; D Perrault; P L Walde; V H Bramwell; M Poljicak; N Boyd; D Warr; B D Norris; D Bowman; G R Armitage; H Weizel; R A Buckman
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

3.  [Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].

Authors:  F Cavalli; M Beer; G Martz; W F Jungi; P Alberto; J P Obrecht; B Mermillod; K W Brunner
Journal:  Schweiz Med Wochenschr       Date:  1982-05-29

4.  Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.

Authors:  B Fisher; C Redmond; S Legault-Poisson; N V Dimitrov; A M Brown; D L Wickerham; N Wolmark; R G Margolese; D Bowman; A G Glass
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

5.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.

Authors:  B Fisher; C Redmond; A Brown; D L Wickerham; N Wolmark; J Allegra; G Escher; M Lippman; E Savlov; J Wittliff
Journal:  J Clin Oncol       Date:  1983-04       Impact factor: 44.544

6.  The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

Authors:  M Castiglione-Gertsch; C Johnsen; A Goldhirsch; R D Gelber; C M Rudenstam; J Collins; J Lindtner; A Hacking; H Cortes-Funes; J Forbes
Journal:  Ann Oncol       Date:  1994-10       Impact factor: 32.976
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.